NEW YORK (GenomeWeb News) – Cancer detection company Oncimmune today said that it has received Medicare coverage for a new blood-based test that it claims can detect cancers as much as five year earlier than current testing methods.
The test is based on a technique that replicates the cancer proteins that trigger the body's response to the disease and robotic technology that measures this response. The technology, called immuno-biomarkers, is based on work by John Robertson, a professor of surgery at the University of Nottingham's Faculty of Medicine and Health Sciences.
The company's test for lung cancer, called EarlyCDT-Lung will be launched in the US this month and in the UK early next year, Oncimmune said. It has obtained Medicare reimbursement for the test and will bill private insurers for it, it added.
Oncimmune licensed annexin biomarkers from Proteome Sciences last year for the test.
In a statement, Proteome Sciences said that Medicare's decision to cover the lung cancer test, which costs $475, "should make a substantial difference to the sales and the market size of the blood test."
The company will receive a royalty payment for each test sold.